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Summary Analysis of conditioned media generated by weakly and highly tumorigenic SKv-1 keratinocyte
lines harbouring integrated human papillomavirus type 16 (HPV16) DNA sequences revealed a factor
inhibiting TNF-a and TNF-,B cytotoxic activity. This inhibitory activity was specifically blocked by htr-9
monoclonal antibody (MAb) recognising 55/60 kDa type I TNF receptor suggesting that it is related to a
soluble form of this particular receptor (sTNF-RI). The presence of sTNF-RI was confirmed by Western blot
analysis of SKv-1 cell-conditioned medium showing a band of 31.5 kDa as well as by the specific enzyme-
linked immunobiological assay (ELIBA). Release of sTNF-RI was a result of shedding because Northern blot
analysis showed that SKv-1 cells expressed a full-length TNF-RI mRNA, and radioimmunoprecipitation of
TNF-RI from [32S]cysteine-labelled cell extracts demonstrated the presence of normal 55 kDa molecule.
Evaluation by ELIBA showed that highly tumorigenic SKv-12 cells released significantly more sTNF-RI than
their weakly tumorigenic SKv-i 1 parental cells. Furthermore, human recombinant as well as SKv cell-derived
sTNF-RI stimulated proliferation of weakly tumorigenic SKv- 11 cells. This suggests that a progressive growth
of some neoplastic cells may be, at least partially, a result of an increased spontaneous release of sTNF-RI that
enables the cells to escape from local TNF-a-mediated growth inhibition.
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Certain types of human papillomaviruses (HPVs) are known
to be associated with intraepithelial neoplasia of the cervix
and external genitalia (Jenson and Lancaster, 1990; Kiviat
and Koutsky, 1993). These lesions usually display a slow,
self-limited growth and frequently regress, either sponta-
neously or after treatment. However, some persisting lesions
induced by 'high-risk' HPV types e.g. HPV 16, 18, 31 and 33,
may evolve into invasive carcinomas (zur Hausen, 1989;
Howley, 1991). The evidence accumulates that growth and
dissemination of HPV-associated lesions are under control of
local and/or systemic immune surveillance (Jablonska et al.,
1989; Pfister, 1990). Especially, local production of immuno-
regulatory anti-tumour cytokines, e.g. TNF-a, IL-6 and
TGF-f1, may play an important role. These cytokines were
shown to be expressed by HPV-harbouring keratinocytes and
may directly or indirectly affect growth of the transformed
cells (Woodworth et al., 1990; Majewski et al., 1991;
Malejczyk et al., 1991, 1992). Accordingly, a non-tumori-
genic SKv keratinocyte cell line established from vulvar
intraepithelial neoplasia and harbouring and expressing
integrated HPV16 DNA sequences (Schneider-Maunoury et
al., 1987; 1990) has been found to release TNF-a
spontaneously which in turn exerted an autocrine growth
inhibitory effect (Malejczyk et al., 1992). These results
strongly suggest the existence of an autocrine TNF-a-
mediated mechanism which could be, at least partially,
responsible for self-limited growth and eradication of certain
HPV-associated tumours.
Progressive growth and dissemination of HPV-induced
lesions may be, at least partially, related to escape from local
cytokine-mediated surveillance. Indeed, highly tumorigenic
HPV-harbouring epithelial cells have been found to be
resistant to anti-proliferative activity of TGF-,B (Wood-
worth et al., 1990; Braun et al., 1990). Similarly,
spontaneous tumorigenic progression of SKv cells was found
to be associated with loss of susceptibility to autocrine TNF-
a-mediated growth limitation (Malejczyk et al., 1994). This
phenomenon was, at least partially, related to a lowered type
I TNF receptor (TNF-RI) expression, however, it could also
depend on release of some TNF-cx inhibitory activity.
Therefore, the aim of the present study was to investigate
whether increased proliferation and tumorigenicity of SKv
cells are associated with an ability to release TNF inhibitory
factor(s).
Materials and methods
Reagents
Recombinant human TNF-a (rhTNF-a; specific activity
2 x 107 U mg-') was generously provided by BASF/Knoll
(Ludwigshafen, Germany) and recombinant human TNF-,B
(rhTNF-fl; specific activity 3 x 107 U mg-1) was purchased
from Genzyme (Boston, MA, USA). Monoclonal htr-9 and
utr-1 antibodies specific for type I (55/60 kDa) and type II
(75/80 kDa) human TNF-R (TNF-RI and TNF-RII)
respectively (Brockhaus et al., 1990), were generously
donated by Dr M Brockhaus of F Hoffmann-LaRoche
(Basle, Switzerland). Recombinant human type I soluble
TNF receptor (rhsTNF-RI; the same as used as a standard
for sTNF-RI enzyme-linked immunobiological assay) also
originated from F Hoffmann-LaRoche. Radiolabelled [35S]L-
cysteine (specific radioactivity >600 Ci mmol-') was
obtained from Amersham (Buckinghamshire, UK).
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SKv cell lines
SKv keratinocytes harbouring integrated HPV16 DNA
sequences were established from vulvar intraepithelial
neoplasia. The SKv-1 ('late') cells used in this study display
about 10-20 HPV16 genome equivalents resulting from
amplifications of a single viral genome insert together with
flanking cellular sequences integrated at single chromosome
12q14-ql5 (Schneider-Maunoury et al., 1987; Sastre-Garau
et al., 1990) and express E6 and E7 viral transforming
proteins (Schneider-Maunoury et al., 1990). Two SKv-1
sublines were studied (Malejczyk et al., 1994). The first,
SKv-l parental subline, was weakly tumorigenic and after
transplantation into nu/nu mice formed the very slowly
growing epidermoid cysts with features of Bowen's carcino-
ma in situ. The second, SKv-12 line, has been derived from a
rapidly growing tumour arising spontaneously after passaging
of parental SKv-Il cells in nu/nu mice. SKv-12 cells were
highly tumorigenic and formed tumours with features of
invasive carcinoma. Both SKv-1 cells were propagated in
vitro in minimal essential medium (MEM) supplemented with
10% fetal calf serum (FCS), 2 mM L-glutamine, 10 mM
HEPES and 1% antibiotic -antimycotic solution (GIBCO
BRL, Paisley, UK) as described previously (Malejczyk et al.,
1992).
Evaluation of SKv cell growth
Proliferation of SKv cells either in culture medium alone or
with addition of the tested factors was assessed after 48 h by
counting the cell number increase in triplicate wells of 24-well
tissue culture plates as described (Malejczyk et al., 1992,
1994).
Fast protein liquid chromatography (FPLC) fractionation of
SKv cell-conditioned media (CM)
For generation of CM, nearly confluent SKv cells were
cultured in serum-free culture medium for 48 h. Then cell-free
supernatants were harvested, filter sterilised, and stored
frozen at -80°C until used for FPLC fractionation. SKv
cell-CM were concentrated about 30-50 times using the
Amicon cell with 10 kDa cut-off membrane (Amicon,
Danvers, MA, USA). For molecular weight fractionation,
150 ,l samples of concentrated SKv cell-CM were subjected
to FPLC gel filtration using Bio-Sil TSK guard and Bio-Sil
TSK-125 columns (Bio-Rad Laboratories, Richmond, CA,
USA). Elution was carried out with phosphate-buffered saline
(PBS, pH 7.4) at flow rate 1 ml min-' and 0.5 ml fractions
were collected (Malejczyk et al., 1992). For anion-exchange
chromatography, 5 ml of concentrated CM was applied onto
Mono Q HR 5/5 column (Pharmacia, Uppsala, Sweden).
Elution was carried out with a continuous 0 to 1 M sodium
chloride gradient in 25 mM PIPES buffer (pH 7.2) at flow
rate 1 ml min-1 and 0.5 ml fractions were collected. Column
fractions were diluted with culture medium and kept frozen
until used for further determinations.
Evaluation of TNF inhibitory activity
TNF inhibitory activity in FPLC fractions was evaluated in
the presence of 5 U ml-1 of rhTNF-cx or rhTNF-,B using a
conventional TNF bioassay with actinomycin-D-treated L929
cells (Kramer and Carver, 1986). The activity of the inhibitor
was expressed in neutralising units (NU), where 1 NU was
defined as the highest dilution of the tested material sufficient
to neutralise cytotoxic activity exerted by 1 U of TNF-a or
TNF-,B.
Northern blot analysis
The cells were lysed in 4 M guanidine isothiocyanate
containing 0.1 M 2-mercaptoethanol (2-ME) and total RNA
was isolated over a caesium chloride cushion. RNA samples
were then separated by a gel electrophoresis in 1% agarose
under denaturing conditions, transferred onto nitrocellulose
membranes and prehybridised as described previously
(Malejczyk et al., 1992). The presence of TNF-RI and
TNF-RII mRNA was detected by hybridisation, with 32p_
labelled probes prepared from 1.0 Kb EcoRI and 0.64 kb
NotI-BglII specific cDNA fragments (Smith et al., 1990)
respectively (kindly provided by Dr S Gillis, Immunex,
Seattle, WA, USA), using RPN 1601 multiprime DNA
labelling system (Amersham). After hybridisation, blots were
washed in stringent conditions and exposed to X-Omat AR
Kodak film at -80°C for 5 days. For control of the RNA
amount applied onto each lane, the blots were rehybridised
(Maejewski et al., 1991) with 1.15 kb PstI /3-actin cDNA
probe (Alonso et al., 1983) and exposed for 3 days.
Radioimmunoprecipitation and Western blot analysis
For analysis of cell-associated TNF-R, SKv cells grown in
6 cm plastic dishes (Corning, UK) and were metabolically
labelled with 0.5 mCi ml-' [35S]cysteine in FCS-, methionine-
and cysteine-free MEM for 2 h. After labelling, an
unincorporated isotope was removed by washing the cells
twice in cold TRIS-saline (pH 7.4) and the cells were lysed in
0.5 ml of complete RIPA buffer consisting of 10 mM Tris-
HCl, 0.15 M sodium chloride, 1% Triton X-100, 1%
deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 0.2 mM
phenylmethylsulphonyl fluoride, and 0.005% aprotinin
(pH 7.5) (Schneider-Maunoury et al., 1990). Then the cell
extracts were cleared by centrifugation and 200 pl of soluble
material was incubated with 10 jug of either htr-9 or utr-I
MAb at 4°C overnight. Precipitation of antigen-MAb
complexes was done by incubating with 15 Ml of goat anti-
mouse IgG covalently linked to Sepharose 4B beads (Zymed,
San Francisco, CA, USA) at room temperature for 2 h. After
incubation, beads were spun down, washed 4 times in
complete RIPA buffer, boiled under reduced conditions in
sample buffer consisting of 62 mM Tris-HCl, 10% glycerol,
0.0015% bromophenol blue, 3% SDS and 5% 2-ME
(pH 6.8), and subjected to SDS-PAGE as described
(Malejczyk et al., 1992). The '4C-labelled Rainbow protein
molecular weight markers (14.3 -200 kDa, Amersham) served
as standards. Gels were fixed in 50% ethanol-7% acetic
acid, dried and exposed to radiosensitive film at -80'C for 7
days.
For detection and characterisation of soluble TNF-R, the
SKv cell-CM was extensively dialysed, lyophylised and
subjected to SDS-PAGE under reducing conditions as
described (Malejczyk et al., 1992). Separated proteins were
blotted onto nitrocellulose paper (Bio-Rad) and the TNF-RI
and TNF-RII were detected with htr-9 and utr-1 MAb
respectively, followed by amplified alkaline phosphatase
detection system (Bio-Rad).
Evaluation of sTNF-R
The presence of soluble forms of TNF-RI and TNF-RII in
conditioned media taken from SKv cell cultures after
different periods of time was detected and evaluated by
specific enzyme-linked immunobiological assay (ELIBA)
(generously donated by Drs N Drees and H Galatti of F
Hoffmann-La Roche, Basle, Switzerland). The assays were
performed according to the attached manufacturer's proto-
cols.
Results
Detection of SKv cell-derived TNF inhibitory activity
The presence of TNF-ox/TNF-# inhibitory activity in CM
generated in 48 h culture of SKv-12 cells was demonstrated
by FPLC gel filtration followed by L929 cytotoxicity assay
(Figure 1). Both TNF-a and TNF-J inhibitory activities
coeluted as a single peak of 25-35 kDa. This inhibitorySoluble TNF receptor and tumour cell growth
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Figure 1 Detection of TNF-a (---) and TNF-,B (-A-) inhibitor in
fractions from FPLC gel filtration of SKv-12 CM. Concentrated
SKv-12 CM was subjected to FPLC gel filtration as described in
Materials and methods and serial dilutions of 0.5ml fractions
were tested for TNF inhibitor activity in L929 cell bioassay in the
presence of 5 Uml-1 of either rhTNF-a or rhTNF-,B. (-), OD.
factor was further subjected to anion-exchange FPLC (data
not shown), and fractions displaying TNF inhibitory activity
were pooled and served as a source of the enriched factor.
To evaluate whether SKv cell-derived TNF inhibitory
activity may be related to soluble TNF receptors, fractions
containing FPLC-enriched factor were incubated with htr-9
and utr-1 MAb recognising type I and type II TNF-R
respectively. As revealed, TNF inhibitory activity was
specifically inactivated by htr-9 MAb (data not shown). On
the other hand, incubation with utr-l MAb did not affect the
TNF inhibitory activity.
Expression of TNF-R and evaluation ofsTNF-R release by
SKv cells
Expression of TNF-R by SKv-1 cells was studied by
Northern blot and radioimmunoprecipitation methods. As
can be seen on Figure 2a, hybridisation with TNF-RI cDNA
a b
1 2
TNF-Ri
,B-Actin
1 2
-2.5-kb
-2.0 kb
probe showed that both SKv-Il and SKv-12 cells expressed a
single 2.5 kb species of specific mRNA. In line with our
previous observation (Malejczyk et al., 1994), the levels of
specific steady-state mRNA were higher in SKv-Il than in
SKv-12 cells. This difference was not caused by an unequal
amount of RNA loaded onto each lane in as much as
rehybridisation with ,B-actin cDNA probe showed similar
amounts of specific ,B-actin mRNA. Similarly, radioimmuno-
precipitation of TNF-RI from SKv-11 and SKv-12 cell
extracts with htr-9 MAb also revealed only a single specific
band corresponding to Mr of 55 000 (Figure 2b). The amount
of TNF-RI was slightly higher in SKv-11 cells.
Neutralisation of SKv-1 cell-derived TNF inhibitory
activity by htr-9 MAb strongly suggested that it may be
related to sTNF-RI. Therefore, the presence of sTNF-RI in
SKv cell-CM was evaluated by the Western blot method and
specific ELIBA. Indeed, Western blot analysis of SKv-Il and
SKv-12 cell-CM showed the presence of a single htr-9-
immunoreactive band corresponding to Mr of 31 500 (Figure
2c). The intensity of the band was significantly higher in the
case of SKv-12 cells. Spontaneous production of sTNF-RI by
SKv-1 cells was further demonstrated by the specific ELIBA
(Figure 3). Evaluation of the kinetics of sTNF-RI release by
SKv-1 cells showed that the amount of the factor increased
with time of culture reaching a plateau after 48 h. In accord
with the results obtained by the Western blot method, there
were significant differences (at least at P < 0.01 by
Wilcoxon's test) in sTNF-RI release between highly
tumorigenic SKv-12 cells and their weakly tumorigenic
SKv-11 parental cells. SKv-12 cells released about 2-fold
more sTNF-RI than SKv-il cells (Figure 3).
Neither the specific TNF-RII mRNA nor TNF-RII
protein were detected in SKv-1 cells or SKv-1 cell-CM by
Northern blot, radioimmunoprecipitation, Western blot or
specific ELIBA (data not shown).
Effect ofsTNF-R on proliferation of SKv cells
Compared with weakly tumorigenic SKv-11 parental cells,
SKv-12 cells displayed a significantly higher in vitro
proliferative potential which correlated with their increased
tumorigenic potential (Malejczyk et al., 1994). To evaluate
whether the higher proliferation of SKv-I cells may be related
to some stimulatory activity of sTNF-RI, both SKv-11 and
SKv-12 cells were cultured in the presence of different
c
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Figure 2 Detection of (a) TNF-RI mRNA, (b) cell-bound TNF-RI and (c) cell-conditioned medium-derived sTNF-RI in SKv- 11
(1) and SKv-12 (2) cells. The presence of specific TNF-RI and P-actin mRNA was detected by Northern blot method, cell-bound
TNF-RI was detected by radioimmunoprecipitation, and sTNF-RI was shown by Western blot, as described in Materials and
methods. In both radioimmunoprecipitation and Western blot experiments equal amounts of total protein were applied onto each
lane.Soluble TNF receptor and tumour cell growthI J Malejczyk et al
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Figure 3 Release of sTNF-RI by weakly tumorigenic SKv-i1
(-.-) and highly tumorigenic SKv-12 (-A-) cells. Both sublines of
SKv cells were grown in 10cm tissue culture dishes and cell-free
supernatants were collected after different periods of time. The
amounts of sTNF-RI in SKv CM were evaluated by means of
specific ELIBA and the results were corrected for cell number in
each dish. Figure shows mean+ s.e. of three independent
experiments.
concentrations of rhsTNF-RI. As seen in Figure 4, rhsTNF-
RI exerted a significant (P < 0.01 by non-parametric
Wilcoxon test) dose-dependent stimulatory effect on the
growth of weakly tumorigenic TNF-sensitive SKv-i cells.
On the other hand, it did not significantly affect the
proliferation of highly tumorigenic SKv-12 cells. Heat-
inactivated rhsTNF-RI influenced proliferation of neither
SKv-i nor SKv-12 cells.
FPLC-enriched preparation of SKv cell-derived sTNF-RI-
related TNF inhibitor stimulated proliferation of SKv- 11 cells
in a similar way and to a similar extent as rhsTNF-RI (data
not shown).
Discussion
The results of the present study show that HPV16-harbouring
SKv keratinocytes spontaneously released a factor that
protected L929 cells from the cytotoxic activity of both
TNF-a and TNF-fl. TNF inhibitory molecules have
previously been found in the sera and urine of normal and
febrile patients and were identified as soluble forms of TNF-
R (Engelmann et al., 1990; Lantz et al., 1990; Seckinger et al.,
1990). TNF inhibitory activity of SKv cell-derived factor was
specifically neutralised by htr-9 MAb recognising human
TNF-RI. This strongly suggests that SKv cell-derived TNF
inhibitor is also related to sTNF-RI.
Release of sTNF-RI by SKv-1 cells was confirmed by
Western blot analysis and specific ELIBA. Upon FPLC gel
filtration SKv cell-derived TNF inhibitor displayed a
molecular weight of about 25-35 kDa, and Western blot
analysis with TNF-RI-specific htr-9 MAb has revealed a
single band of 31.5 kDa. This is in agreement with previous
findings on urine-derived sTNF-R as well as sTNF-R
released by cells transfected with full-length TNF-R cDNA
showing that these molecules display a molecular weight in
the range of 27-40 kDa (Engelmann et al., 1989; Kohno et
al., 1990; Seckinger et al., 1990). Since only a single major
species of specific TNF-R mRNA could be identified in
normal and TNF-R cDNA transfected cells (Gray et al.,
1990; Kohno et al., 1990; Nophar et al., 1990), it is plausible
that these sTNF-R originated from shedding of the
membrane-bound receptor. Similarly, Northern blot analysis
of mRNA isolated from SKv cells showed a single signal
corresponding to full-length TNF-RI mRNA. Immunopreci-
pitation of whole SKv cellular extracts with htr-9 MAb also
revealed only one band corresponding to an intact 55 kDa
Figure 4 Effect of normal (-) and heat-inactivated (- - - -)
rhsTNF-RI on proliferation of weakly tumorigenic SKv-11 (---)
and highly tumorigenic SKv-12 (-A-) cells. Inactivation of
rhsTNF-RI was performed at 90°C for 15min and resulted in a
complete loss of its TNF inhibitory activity as revealed by L929
assay. SKv cells were cultured in the presence of different
concentrations of normal and heat-inactivated rhsTNF-RI for
48h and then their number increase was assessed by cell counting
and compared with the cell number increase in the control in
culture medium alone. The results show mean+ s.e. of three
independent experiments. The cell number increase in untreated
control SKv-l 1 and SKv-12 cell cultures was 12.1 + 1.8 and
18.3+2.4 ( x 10-4) respectively.
TNF-RI. This suggests that sTNF-RI released by SKv cells
resulted from neither alternative splicing of specific mRNA
nor intracellular post-translational modifications of TNF-RI
molecule. Accordingly, SKv cell-derived sTNF-RI appears to
be an extracellular ligand-binding domain shed directly from
the cell surface.
The mechanism responsible for spontaneous shedding of
sTNF-RI by SKv cells remains unclear. Shedding of sTNF-R
was found to be induced by various exogenous stimulatory
agents such as phorbol esters, N-formyl Met-Leu-Phe, CSa,
GM-CSF and anti-CD3 MAb and requires endogenous
protein kinase activity (Gray et al., 1990; Porteu and
Nathan, 1990; Crowe et al., 1993). It is plausible that it
results from some proteolytic cleavage of cell-bound TNF-R
(Nophar et al., 1990), and, in the case ofrelease of sTNF-RII
from neutrophils, an elastase is a possible candidate (Porteu
et al., 1991).
Highly tumorigenic SKv-12 cells released significantly
more sTNF-RI than their weakly tusnorigenic SKv- 1I
parental cells. In as much as the amount of the steady-state
TNF-RI mRNA and cell-bound TNF-RI protein in SKv-12
cells were found to be significantly lower than in SKv-11
cells, this phenomenon cannot be explained simply as being
related to a higher level of TNF-RI expression by SKv-12
cells. The malignant phenotype of a variety of neoplastic cells
is associated with increased endogenous protein kinase
activity and an excessive release of proteolytic enzymes
(Strauli et al., 1980; Bishop, 1991). Accordingly, an increased
release rate of sTNF-RI might be caused by a higher protein
phosphorylation rate and/or extracellular protease activity
associated with the more malignant phenotype of SKv-12
cells. However, a putative protease that could be responsible
for releasing the sTNF-RI from SKv cells is unknown.
Spontaneous release of sTNF-R/TNF inhibitor has been
observed in some tumour cell lines (Aderka et al., 1991).
Furthermore, significantly increased levels of sTNF-R were
detected in the sera of patients with various neoplastic
diseases (Aderka et al., 1991; Waage et al., 1992).
Physiological and immunopathological significance of this
phenomenon is unknown. However, it is tempting to
speculate that sTNF-R may exert a tumour protecting
effect: (1) shedding of surface-bound TNF-R from tumour
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cells may lead to their desensitisation to circulating TNF, and
(2) sTNF-R may neutralise biological anti-tumour activity of
the locally released TNF.
Accordingly, release of higher amounts of sTNF-RI by
highly tumorigenic SKv-12 cells was accompanied by their
higher in vitro proliferation and correlated with their relative
TNF-resistance and higher tumorigenic potential (Malejczyk
et al., 1994). Furthermore, treatment of weakly tumorigenic,
TNF-sensitive SKv-l 1 parental cells with rhsTNF-RI or SKv
cell-derived TNF inhibitor resulted in a significant dose-
dependent stimulation oftheir growth. This effect was specific
and heat-inactivation of rhsTNF-RI resulted in loss of its
growth stimulatory effect on SKv-l 1 cells. In as much as SKv
cells spontaneously express and release TNFE- which, in turn,
exerts an autocrine anti-proliferative effect (Malejczyk et al.,
1992), the stimulatory effect ofsTNF-RI on SKv-l 1 cells may
be explained as caused by neutralisation of the endogenous
cytokine. Thus, it is plausible that an increased proliferative
potential and high tumorigenicity of SKv-12 cells may be, at
least partially, related to an excessive release of sTNF-RI.
These results strongly support a view that sTNF-R may
enable tumour cell escape from local TNF-z-mediated
surveillance and may be one of the important factors
facilitating progressive growth of certain neoplastic lesions.
Abbrevaloms
CM, conditioned medium; ELIBA, enzyme-linked immunobiolo-
gical assay; FPLC, fast protein liquid chromatography; HPV,
human papillomavirus; MAb, monoclonal antibody; NU, neutra-
lising unit; sTNF-R, soluble tumour necrosis factor receptor.
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